

年間業績 2023 年 10 月～2024 年 9 月

論文発表

原著

1. Nakanishi T, Yoneshima Y, Okamura K, Yanagihara T, Hashisako M, Iwasaki T, Haratake N, Mizusaki S, Ota K, Iwama E, Takenaka T, Tanaka K, Yoshizumi T, Oda Y, Okamoto I. MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma. *Cancer Sci*. 2023 Oct; 114(10): 4101-4113.
2. Wakuda K, Yamaguchi H, Kenmotsu H, Fukuda M, Ito K, Tsuchiya-Kawano Y, Tanaka K, Harada T, Nakatani Y, Miura S, Yokoyama T, Nakamura T, Izumi M, Nakamura A, Ikeda S, Takayama K, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K. A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L). *JTO Clin Res Rep*. 2023 Oct; 4(12): 100587.
3. Nakajima M, Tanaka K, Yoneshima Y, Yamashita S, Shibahara D, Iwama E, Okamoto I. YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells. *Biochem Biophys Res Commun*. 2023 Nov; 681: 120-126.
4. Hagihara Y, Tomioka Y, Suetsugu T, Shinmura M, Misono S, Goto Y, Kikkawa N, Kato M, Inoue H, Mizuno K, Seki N. Identification of Tumor-Suppressive miR-139-3p-Regulated Genes: TRIP13 as a Therapeutic Target in Lung Adenocarcinoma. *Cancers (Basel)*. 2023 Nov; 15(23): 5571.
5. Takei R, Yamano Y, Kataoka K, Fukihara J, Sasano H, Yokoyama T, Matsuda T, Kimura T, Kondoh Y. Disease progression and changes in KL-6 in patients with limited cutaneous systemic sclerosis-associated interstitial lung disease. *Respir Investig*. 2024 Jan; 62(1): 44-48.
6. Hamu-Tanoue A, Takagi K, Taketomi Y, Miki Y, Nishito Y, Kano K, Aoki J, Matsuyama T, Kondo K, Dotake Y, Matsuyama H, Machida K, Murakami M, Inoue H. Group III secreted phospholipase A2 -driven lysophospholipid pathway

protects against allergic asthma. *FASEB J.* 2024 Jan; 38(2): e23428.

7. 松山崇弘, 田中 淳, 戸根 一哉, 清水 薫子, 中野 貴子, 高橋 浩一郎. CQ4 中等症から重症の成人喘息患者の長期管理において,気管支熱形成術は有用か. *アレルギー*. 2024.2; 73(1): 40-51.
8. Okamoto K, Kogirima M, Tsuji Y, Ishino S, Inoue H. The impact of energy and protein intake on rehabilitation efficiency in convalescent patients. *Asia Pac J Clin Nutr.* 2024 Mar; 33(1): 33-38.
9. Ibusuki R, Iwama E, Shimauchi A, Tsutsumi H, Yoneshima Y, Tanaka K, Okamoto I. TP53 gain-of-function mutations promote osimertinib resistance via TNF- α -NF- κ B signaling in EGFR-mutated lung cancer. *NPJ Precis Oncol.* 2024 Mar; 8(1): 60.
10. Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, Laktionov K, Yang TY, Yu Y, Kato T, Jiang L, Chewaskulyong B, Lucien Geater S, Maurel JM, Rojas C, Takahashi T, Havel L, Shepherd FA, Tanaka K, Ghiorghiu D, Amin NP, Armenteros-Monterroso E, Huang X, Chaudhry AA, Yang JC. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol.* 2024 Mar; 42(7): 808-820.
11. Sato T, Furukawa T, Teramachi R, Fukihara J, Yamano Y, Yokoyama T, Matsuda T, Kataoka K, Kimura T, Sakamoto K, Ishii M, Kondoh Y. Mild elevation of pulmonary vascular resistance predicts mortality regardless of mean pulmonary artery pressure in mild interstitial lung disease. *Thorax.* 2024 Apr; 79(5): 422-429.
12. Inutsuka Y, Iwama E, Shiraishi Y, Yoneshima Y, Shibahara D, Tanaka K, Okamoto I. Osimertinib readministration for central nervous system metastases in non-small cell lung cancer positive for EGFR activating mutations. *Respir Investig.* 2024 May; 62(3): 334-338.
13. Ogo N, Ikegame S, Hotta T, Kan-OK, Yoneshima Y, Shiraishi Y, Tsubouchi K, Tanaka K, Okamoto I. The Utility and Limitations of Universal Polymerase Chain Reaction Screening for SARS-CoV-2 During Hospital Admission. *Cureus.*

2024 May; 16(5): e61470.

14. 福泉 彩, 赤松 弘朗, 朝倉 啓介, 小暮 啓人, 榊原 里江, 新納 英樹, 山田 忠明, 佐々木 高明, 竹中 朋祐, 田中 謙太郎, 田中雄悟, 野津田 泰嗣, 秦 明登, 福井 麻里子, 古本秀行, 土田 正則. 2023 年度日本肺癌学会会員におけるアーリーキャリアに関するアンケート調査結果. *肺癌*. 2024.6; 64(3): 151-157.
15. Bando T, Takei R, Fukihara J, Sasano H, Yamano Y, Yokoyama T, Matsuda T, Kataoka K, Kimura T, Fukuoka J, Hatabu H, Johkoh T, Kondoh Y. Idiopathic Pulmonary Fibrosis Incidentally Detected by Computed Tomography Scan as Interstitial Lung Abnormalities. *Ann Am Thorac Soc*. 2024 Jun; 21(6): 983-985.
16. Kawatoko K, Washio Y, Ohara T, Fukuyama S, Honda T, Hata J, Nakazawa T, Kan-OK, Inoue H, Matsumoto K, Nakao T, Kitazono T, Okamoto I, Ninomiya T. Risks of dementia in a general Japanese older population with preserved ratio impaired spirometry: The Hisayama Study. *J Epidemiol*. 2024 Jul; 34(7): 331-339.
17. Kakiuchi Y, Saruwatari K, Murotani K, Tokito T, Iriki T, Iwakawa J, Sakata Y, Shingu N, Saeki S, Inaba M, Takaki A, Misono S, Suetsugu T, Azuma K, Mizuno K, Sakagami T. Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study. *Clin Lung Cancer*. 2024 Jul; S1525-7304: (24)00139-6.
18. Waterhouse DM, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, van den Heuvel MH, Linardou H, Chul Cho B, Roberts-Thomson R, Tanaka K, Blais N, Schvartsman G, Holmskov Hansen K, Chmielewska I, Forster MD, Giannopoulou C, Stollenwerk B, Obiozor CC, Wang Y, Novello S. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. *Lung Cancer*. 2024 Aug; 196: 107921.
19. Shibahara D, Tanaka K, Togao O, Shiraishi Y, Yoneshima Y, Iwama E, Yoshitake T, Ishigami K, Okamoto I. Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer. *Clin Lung Cancer*. 2024 Sep; 25(6): 581-586.

20. Tomioka Y, Seki N, Suetsugu T, Hagihara Y, Sanada H, Goto Y, Kikkawa N, Mizuno K, Tanaka K, Inoue H. Identification of Tumor Suppressive miR-144-5p Targets: FAM111B Expression Accelerates the Malignant Phenotypes of Lung Adenocarcinoma. *Int J Mol Sci*. 2024 Sep; 25(18): 9974.

21. Matsuyama T, Matsuyama H, Dotake Y, Oniwa O, Tsuruzono K, Uchida H, Yasuda S, Kondo K, Takagi K, Suetsugu T, Iwakawa J, Machida K, Mizuno K, Tanaka K, Inoue H. Long-term efficacy of mepolizumab on eosinophilic granulomatosis with polyangiitis: a retrospective study. *Explor Asthma Allergy*. 2024 Sep; 2: 461-72.

22. Matsuda T, Kondoh Y, Takei R, Sasano H, Fukihara J, Yamano Y, Yokoyama T, Kataoka K, Watanabe F, Kimura T. Responsiveness and minimal clinically important difference of the COPD Assessment Test in fibrotic interstitial lung disease. *Respir Investig*. 2024 Sep; 62(6): 1088-1093.

23. Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. *J Clin Oncol*. 2024 Sep; 9: 2401544.

総説

1. 松山 崇弘, 井上 博雅 : ICS/ホルモテロール頓用治療の功罪. *Medical Practice*. 2024.1; 41(1) 96-99.

2. Matsuyama T, Salter BM, Emami Fard N, Machida K, Sehmi R : TNF Superfamily and ILC2 Activation in Asthma. *Biomolecules*. 2024 Feb; 14(3): 294.

症例

1. Tsuneoka Y, Tanaka K, Shimauchi A, Inoue S, Yoneshima Y, Ikegame S, Harada E,

- Okamoto I : A Case of Obstructing Bronchial Aspergillosis in a Patient Receiving Cytotoxic Chemotherapy and Inhaled Corticoid Therapy. *Respir Endosc.* 2023.Oct; 1 (2): 105-108.
2. Matsuyama T, Oniwa M, Tsuruzono K, Yasuda S, Yone M, Tomioka Y, Uchida A, Mitsuyama H, Kubota S, Suetsugu T, Mizuno K, Inoue H : Improving visual acuity with nivolumab plus ipilimumab plus two cycles of chemotherapy following a diagnosis of lung adenocarcinoma with choroidal metastasis: A case report and literature review. *Respirol Case Rep.* 2023 Nov 30; 12(1): e01262.
 3. Hagihara Y, Suetsugu T, Uto H, Kozono T, Masada Y, Satozono Y, Shinmura M, Koreeda Y, Mizuno K, Inoue H : Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E mutation associated with osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma: A case report. *Respir Investig.* 2024 Jan; 62(1): 13-15.
 4. 窪田 幸司, 水野 圭子, 宮田 真里奈, 新村 昌弘, 濱崎 哲郎, 井上 博雅 : 発熱と組織球主体の滲出性胸水で発症した TAFRO 症候群の 1 例. *日本呼吸器学会誌(2186-5876)*. 2024.01; 13 巻 1 号: 44-48.
 5. Sakoda S, Tanaka K, Koga Y, Mikumo H, Tsuchiya-Kawano Y, Harada E, Tamiya S, Okamoto I : A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib. *Thorac Cancer.* 2024 Feb; 15(5): 415-418.
 6. Nakahara S, Ishii Y, Egashira R, Tsubouchi K, Kohno M, Takenaka T, Tanaka K, Okamoto I : Lemborexant-induced interstitial lung disease: A case report. *Respirol Case Rep.* 2024 Apr; 12(5): e01334.
 7. Matsuyama T, Kubota K, Tsuruzono K, Uchida H, Hamasaki T, Mizuno K, Inoue H : Primary mediastinal choriocarcinoma requiring differentiation from non-small cell lung cancer: An autopsy case report. *Respir Med Case Rep.* 2024 May; 50: 102037.
 8. Sunanaga Y, Suetsugu T, Nagata Y, Miyata M, Kondo K, Mitsuyama H, Kubota S, Mizuno K, Tanaka K, Inoue H : Cytomegalovirus cavitory pneumonia in a human immunodeficiency virus-infected patient. *Respirol Case Rep.* 2024 May; 12(5):

e01392.

9. Yamamoto Y, Shibahara D, Mori T, Otsubo K, Shiraishi Y, Yoneshima Y, Iwama E, Tanaka K, Oda Y, Okamoto I : Tracheomediastinal fistula induced by concurrent chemoradiotherapy in small cell lung cancer: A case report and literature review. *Thorac Cancer*. 2024 May; 15(13): 1106-1111.